What randomized controlled trials evaluated garaherb and what were their primary endpoints?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Available sources in the provided set do not mention any randomized controlled trials (RCTs) that evaluated a product called “garaherb.” The search results focus on general clinical-trial coverage, trials to watch in 2025, and specific agents like garsorasib — not “garaherb” (not found in current reporting) [1] [2] [3].
1. What the record shows: no RCTs of “garaherb” in these results
A targeted review of the supplied search snippets finds no mention of a compound or product named “garaherb,” nor any randomized controlled trials evaluating it. The documents include overviews of clinical-trial landscapes (Nature Medicine’s list and related “trials to watch” pieces) and trial databases or trackers, yet none name “garaherb” or report primary endpoints for trials of that agent [1] [2] [4].
2. Confusingly similar names appear — verify spelling and identity
One search hit is about “garsorasib,” a KRAS G12C inhibitor studied in phase 1/2 trials for pancreatic cancer; that is a pharmacologic agent with published efficacy and safety reports, but it is not “garaherb” and those trials were not described as randomized controlled trials in the supplied excerpt [3]. If you meant garsorasib, the available source describes phase 1/2 open-label trials (NCT04585035 and NCT05383898) in which patients received 600 mg twice daily; primary endpoints are not listed in the snippet [3].
3. What the provided sources do document — context on clinical-trial reporting
The set includes broad coverage of important trials shaping 2025 (Nature Medicine), collections of clinical-trial reports (Nature journals), and media trackers (BioPharma Dive, Drugs.com) that typically flag late-stage randomized trials and their endpoints; none, however, provide trial-level details about “garaherb” [1] [5] [2] [4]. That pattern suggests either the agent is not covered in these outlets or the name differs in the literature.
4. How to proceed for a definitive answer
To identify RCTs and primary endpoints for a given investigational product, standard next steps include searching clinical trial registries (e.g., ClinicalTrials.gov), peer‑reviewed publications, or FDA/EMA review documents using the exact study drug name, sponsor, or registry identifiers. The supplied dataset does not include those registry searches, so concrete trial identifiers and endpoints for “garaherb” are not available here (not found in current reporting) [6] [7].
5. Potential sources and pitfalls to cross-check
Use trial registries and the sponsor’s press releases to locate randomized trials and their pre‑specified primary endpoints; industry trackers (Drugs.com, BioPharma Dive) and journal collections (Nature Clinical Trials Collection) are useful to corroborate readouts and context [4] [2] [5]. Be alert to near-homonyms: “garsorasib” is documented in these results and could be a source of confusion if names were transcribed incorrectly [3].
6. Limits of this analysis and transparency about missing elements
This report relies solely on the provided search results. The absence of evidence for RCTs of “garaherb” in these materials is not proof that no such trials exist; it only means the supplied sources do not mention them (not found in current reporting) [1] [3]. I did not search external registries or beyond the supplied snippets; those could contain trial registrations, protocols, or publications with primary‑endpoint definitions.
If you want a definitive list of randomized controlled trials and their primary endpoints, provide an alternate spelling, sponsor name, or permission to search registries (ClinicalTrials.gov) and journal databases; with that I can extract trial identifiers, phase, randomization status, and the trial’s pre‑specified primary endpoints.